Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:48:34.261Z.
Calculation as of: 2026-10-06T21:48:34.261Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3426d5a31c39f39b03255f489736213a5d3ef01d64930d1418f7917ed6abe5c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Vor Biopharma Inc.
Market Cap
$992.14M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$996.65M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.69M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$982.46M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Operating Cash Flow Yield
1.39%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$1.01B
Operating Cash Flow Yield
N/A
TTM Avg
1.54%
3Y Avg
13.01%
5Y Avg
70.14%
Market Cap
$978.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Operating Cash Flow Yield
19.27%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
Market Cap
$1.02B
Operating Cash Flow Yield
4.18%
TTM Avg
6.70%
3Y Avg
7.23%
5Y Avg
7.23%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vor Biopharma Inc. (VOR) | $992.14M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 1.39% | 0.99% | 0.99% | 0.99% |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 1.54% | 13.01% | 70.14% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 19.27% | 14.96% | 15.37% | 11.65% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | 4.18% | 6.70% | 7.23% | 7.23% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | N/A | 0.20% | 0.20% | 0.20% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
